Our study encourages adequately powered subgroup analysis of patients with low-positive and intermediate ER expression in clinical trials for ICB in ER-positive breast cancer and highlights that the traditional selection based of breast cancer patients on ER expression might not be optimal for ICB treatment. The gene discussed is ESR1; the disease is breast cancer.